Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for TYKERB
- Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab
- Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer
- Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
- T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer
- Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel
- PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer
- Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery
- Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
- Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib
- Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer
- Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer
- A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
- Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis
- TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.
- Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
- Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer
- ErbB2 Positive Metastatic Breast Cancer
- Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
- Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
- Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
- Physician Liver Function Test (LFT) Monitoring for Tykerb Pts
- Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors
- A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma
- Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only
- Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease
- Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder
- Drug Use Investigation for TYKERB Tablet (All Case Investigation)
- Study of Preoperative Weekly Paclitaxel and Carboplatin With Lapatinib (Tykerb®) in Patients With ErbB2-Positive Stage I-III Breast Cancer
- Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer
- Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast Cancer
- Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer
- Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer
- Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast Cancer
- Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer
- A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer
- Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer
- Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer
- Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer
- Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb®) (PGT)
- GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers
- Lapatinib With Sirolimus or Metformin
- Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck
- Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
- Regulatory TYKERB® Tablets PMS
- Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
- A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium
- Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy
- Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
- Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer
- Concentration and Activity of Lapatinib in Vestibular Schwannomas
- Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
- A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
- Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
- Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
- Phase II Neoadjuvant in Inflammatory Breast Cancer
- Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer
- Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer
- Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC
- Lapatinib and Circulating Tumor Cells in Breast Cancer
- Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer
- LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
- Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery
- LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients
- Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer
- Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma
- Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer
- Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ
- Lapatinib and Trastuzumab With or Without Endocrine Therapy
- Bevacizumab in Multiple Phase I Combinations
- A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase
- Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer
- Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer
- Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer
- GW572016 In Patients With Advanced Or Metastatic Breast Cancer
- Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin
- Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive
- Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors
- Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)
- Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer
- Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
- Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer
- Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
- Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy
- Neoadjuvant GW572016 to Treat Breast Cancer
- Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen
- Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
- Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer
- Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
- S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer
- Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer
- Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
- Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases
- Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
- Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
- Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer
- Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers
Clinical trials list
click for details